Study of IBI3016 in People With Mild or Moderate Hypertension Patients

Prior treatment

• Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
• Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, transient ischemic attack, or clinically significant cardiac arrhythmias within 6 months prior to screening, or a previous diagnosis of decompensated heart failure or New York Heart Association (NYHA) grade III or IV heart failure.
  • Other protocol-defined inclusion/exclusion criteria may apply

Other illness

• Known history of secondary hypertension.
• Current or history of intolerance to ACEi and/or ARBs.

Lab values

• Laboratory parameter assessments outside of range at screening：
  • Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 2× Upper Limit of Normal (ULN)
  • Total Bilirubin \> 1.5× ULN
  • International Normalized Ratio (INR) \> 2.0
  • Serum Potassium \> 5 mmol/L
  • Estimated Glomerular Filtration Rate (eGFR) ≤ 45 mL/min/1.73m²
  • QTcF \> 480 ms

Other

• Orthostatic hypotension.

• Signed informed consent.
• Males or females aged 18 to 75 years. 3 Diagnosed primary hypertension who have not been taking anti-hypertensive medication within 4 weeks prior to informed consent.
  • 4.Mean sitting SBP ≥140 mmHg and \< 170 mmHg measured by OBPM. 5.Participants able to understand and comply with study procedures.